Clostridium difficile 30 years on: what has, or has not, changed and why?

International Journal of Antimicrobial Agents

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Gerding, Dale N ^a,b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Animal models; Antibiotic associated diarrhoea; Binary toxin; Clindamycin colitis; Clostridium difficile; Pseudomembranous colitis; Toxins A and B

Indexed keywords

CEFOXITIN; CEPHALOSPORIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYCLOSERINE; IMMUNOGLOBULIN; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; TOLEVAMER; VANCOMYCIN;

ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CYTOTOXICITY; DISEASE TRANSMISSION; DRUG COST; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME IMMUNOASSAY; GENOTYPE; HUMAN; IMMUNE RESPONSE; LACTOBACILLUS; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; STREPTOCOCCUS;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EUROPE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NORTH AMERICA;

EID: 62249160651     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(09)70008-1     Document Type: Article

References (92)

1. Finney J.M.T. Gastroenterostomy for cicatrizing ulcer of the pylorus. Johns Hopkins Med J 4 (1893) 53-55
2. Hambre D.M., Raki G., McKnee C.M., and MacPhillamy H.B. The toxicity of penicillin as prepared for clinical use. Am J Med Sci 206 (1943) 642-653
3. Pettet J.D., Baggenstoss A.H., Dearing W.H., and Judd Jr. E.S. Postoperative pseudomembranous enterocolitis. Surg Gynecol Obstet 98 (1954) 546-552
4. Goulston S.J.M., and McGovern V.J. Pseudo-membranous colitis. Gut 6 (1965) 207-212
5. Scott A.J., Nicholson G.I., and Kerr A.R. Lincomycin as a cause of pseudomembranous colitis. Lancet 2 (1973) 1232-1234
6. Tedesco F.J., Barton R.W., and Alpers D.H. Clindamycin-associated colitis. A prospective study. Ann Intern Med 81 (1974) 429-433
7. Hall J.C., and O'Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 49 (1935) 390-402
8. Hafiz S. Clostridium difficile and its toxins [PhD Thesis]. Leeds: Department of Microbiology, University of Leeds; 1974.
9. Larson H.E., Parry J.V., Price A.B., Davies D.R., Dolby J., and Tyrrell D.A. Undescribed toxin in pseudomembranous colitis. Br Med J 1 (1977) 1246-1248
10. Bartlett J.G., Onderdonk A.B., and Cisneros R.L. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology 73 (1977) 772-776
11. Rifkin G.D., Fekety F.R., and Silva Jr. J. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 2 (1977) 1103-1106
12. Larson H.E., and Price A.B. Pseudomembranous colitis: Presence of clostridial toxin. Lancet 2 (1977) 1312-1314
13. Bartlett J.G., Chang T.W., Gurwith M., Gorbach S.L., and Onderdonk A.B. Antibioticassociated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298 (1978) 531-534
14. George W.L., Sutter V.L., Goldstein E.J., Ludwig S.L., and Finegold S.M. Aetiology of antimicrobial-agent-associated colitis. Lancet 1 (1978) 802-803
15. Larson H.E., Price A.B., Honour P., and Borriello S.P. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1 (1978) 1063-1066
16. Bartlett J.G. Introduction. In: Rolfe R.D., and Finegold S.M. (Eds). Clostridium difficile: Its role in intestinal disease (1988), Academic Press, San Diego 11-12
17. Lyerly D.M., Lockwood D.E., Richardson S.H., and Wilkins T.D. Biological activities of toxins A and B of Clostridium difficile. Infect Immun 35 (1982) 1147-1150
18. Lyerly D.M., Saum K.E., MacDonald D.K., and Wilkins T.D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47 (1985) 349-352
19. Riegler M., Sedivy R., Pothoulakis C., Hamilton G., Zacherl J., Bischof G., et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 95 (1995) 2004-2011
20. Just I., Selzer J., Wilm M., von Eichel-Streiber C., Mann M., and Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375 (1995) 500-503
21. Just I., Selzer J., von Eichel-Streiber C., and Aktories K. The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest 95 (1995) 1026-1031
22. Dove C.H., Wang S.Z., Price S.B., Phelps C.J., Lyerly D.M., Wilkins T.D., et al. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun 58 (1990) 480-488
23. von Eichel-Streiber C., Laufenberg-Feldmann R., Sartingen S., Schulze J., and Sauerborn M. Cloning of Clostridium difficile toxin B gene and demonstration of high N-terminal homology between toxin A and B. Med Microbiol Immunol 179 (1990) 271-279
24. Hundsberger T., Braun V., Weidmann M., Leukel P., Sauerborn M., and von EichelStreiber C. Transcription analysis of the genes tcdA E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 244 (1997) 735-742
25. Hammond G.A., Lyerly D.M., and Johnson J.L. Transcriptional analysis of the toxigenic element of Clostridium difficile. Microb Pathog 22 (1997) 143-154
26. Mani N., and Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 98 (2001) 5844-5849
27. Matamouros S., England P., and Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 64 (2007) 1274-1288
28. Browne R.A., Fekety Jr. R., Silva Jr. J., Boyd D.I., Work C.O., and Abrams G.D. The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J 141 (1977) 183-192
29. Chang T.W., Bartlett J.G., Gorbach S.L., and Onderdonk A.B. Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun 20 (1978) 526-529
30. Larson H.E., Price A.B., and Borriello S.P. Epidemiology of experimental enterocecitis due to Clostridium difficile. J Infect Dis 142 (1980) 408-413
31. Wilson K.H., and Sheagren J.N. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis 147 (1983) 733-736
32. Borriello S.P., and Barclay F.E. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol 19 (1985) 339-350
33. Mulligan M.E., Rolfe R.D., Finegold S.M., and George W.L. Contamination of a hospital environment by Clostridium difficile. Curr Microbiol 3 (1979) 173-175
34. Kim K.H., Fekety R., Batts D.H., Brown D., Cudmore M., Silva Jr. J., and Waters D. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 143 (1981) 42-50
35. Gerding D.N., Olson M.M., Peterson L.R., Teasley D.G., Gebhard R.L., Schwartz M.L., et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 146 (1986) 95-100
36. McFarland L.V., Mulligan M.E., Kwok R.Y., and Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989) 204-210
37. Johnson S., Clabots C.R., Linn F.V., Olson M.M., Peterson L.R., and Gerding D.N. Nosocomial Clostridium difficile colonisation and disease. Lancet 336 (1990) 97-100
38. Clabots C.R., Johnson S., Bettin K.M., Mathie P.A., Mulligan M.E., Schaberg D.R., et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 31 (1993) 1870-1875
39. Clabots C.R., Johnson S., Olson M.M., Peterson L.R., and Gerding D.N. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166 (1992) 561-567
40. Shim J.K., Johnson S., Samore M.H., Bliss D.Z., and Gerding D.N. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351 (1998) 633-636
41. Hirschhorn L.R., Trnka Y., Onderdonk A., Lee M.L., and Platt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 169 (1994) 127-133
42. Surveillance for community-associated Clostridium difficile Connecticut, 2006. MMWR Morb Mortal Wkly Rep 57 (2008) 340-343
43. Severe Clostridium difficile-associated disease in populations previously at low risk four states, 2005. MMWR Morb Mortal Wkly Rep 54 (2005) 1201-1205
44. Dial S., Delaney J.A., Barkun A.N., and Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. J Am Med Assoc 294 (2005) 2989-2995
45. Dial S., Delaney J.A., Schneider V., and Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175 (2006) 745-748
46. Wilcox M.H., Mooney L., Bendall R., Settle C.D., and Fawley W.N. A case control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 62 (2008) 388-396
47. Brazier J.S. The epidemiology and typing of Clostridium difficile. J Antimicrob Chemother 41 Suppl C (1998) 47-57
48. Johnson S., Adelmann A., Clabots C.R., Peterson L.R., and Gerding D.N. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 159 (1989) 340-343
49. Samore M.H., Bettin K.M., DeGirolami P.C., Clabots C.R., Gerding D.N., and Karchmer A.W. Wide diversity of Clostridium difficile types at a tertiary referral hospital. J Infect Dis 170 (1994) 615-621
50. Johnson S., Samore M.H., Farrow K.A., Killgore G.E., Tenover F.C., Lyras D., et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 341 (1999) 1645-1651
51. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
52. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile- associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
53. Johnson S., Gerding D.N., Olson M.M., Weiler M.D., Hughes R.A., Clabots C.R., et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 88 (1990) 137-140
54. Brooks S.E., Veal R.O., Kramer M., Dore L., Schupf N., and Adachi M. Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol 13 (1992) 98-103
55. Mayfield J.L., Leet T., Miller J., and Mundy L.M. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 31 (2000) 995-1000
56. Pear S.M., Williamson T.H., Bettin K.M., Gerding D.N., and Galgiani J.N. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 120 (1994) 272-277
57. McNulty C., Logan M., Donald I.P., Ennis D., Taylor D., Baldwin R.N., et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 40 (1997) 707-711
58. Silva Jr. J., Batts D.H., Fekety R., Plouffe J.F., Rifkin G.D., and Baird I. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med 71 (1981) 815-822
59. Teasley D.G., Gerding D.N., Olson M.M., Peterson L.R., Gebhard R.L., Schwartz M.J., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2 (1983) 1043-1046
60. Fekety R., Silva J., Kauffman C., Buggy B., and Deery H.G. Treatment of antibioticassociated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 86 (1989) 15-19
61. Johnson S., Homann S.R., Bettin K.M., Quick J.N., Clabots C.R., Peterson L.R., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117 (1992) 297-302
62. Zar F.A., Bakkanagari S.R., Moorthi K.M., and Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007) 302-307
63. Chang T.W., Bartlett J.G., Gorbach S.L., and Onderdonk A.B. Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun; 20 (1978) 526-529
64. George W.L., Sutter V.L., Citron D., and Finegold S.M. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 9 (1979) 214-219
65. Lyerly D.M., Sullivan N.M., and Wilkins T.D. Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol 17 (1983) 72-78
66. Lyerly D.M., Phelps C.J., and Wilkins T.D. Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol 21 (1985) 12-14
67. Lyerly D.M., Barroso L.A., and Wilkins T.D. Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol 29 (1991) 2639-2642
68. Kato N., Ou C.Y., Kato H., Bartley S.L., Luo C.C., Killgore G.E., et al. Detection of toxigenic Clostridium difficile in stool specimens by the polymerase chain reaction. J Infect Dis 167 (1993) 455-458
69. Alfa M.J., Kabani A., Lyerly D., Moncrief S., Neville L.M., Al-Barrak A., et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol 38 (2000) 2706-2714
70. O'Connor D., Hynes P., Cormican M., Collins E., Corbett-Feeney G., and Cassidy M. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 39 (2001) 2846-2849
71. Delmée M., Van Broeck J., Simon A., Janssens M., and Avesani V. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J Med Microbiol 54 (2005) 187-191
72. Peterson L.R., Manson R.U., Paule S.M., Hacek D.M., Robicsek A., Thomson Jr. R.B., et al. Detection of toxigenic Clostridium difficile in stool samples by realtime polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis 45 (2007) 1152-1160
73. Sloan L.M., Duresko B.J., Gustafson D.R., and Rosenblatt J.E. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol 46 (2008) 1996-2001
74. Ticehurst J.R., Aird D.Z., Dam L.M., Borek A.P., Hargrove J.T., and Carroll K.C. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 44 (2006) 1145-1149
75. Seal D., Borriello S.P., Barclay F., Welch A., Piper M., and Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 6 (1987) 51-53
76. Tvede M., and Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1 (1989) 1156-1160
77. Kotz C.M., Peterson L.R., Moody J.A., Savaiano D.A., and Levitt M.D. Effect of yogurt on clindamycin-induced Clostridium difficile colitis in hamsters. Dig Dis Sci 37 (1992) 129-132
78. Surawicz C.M., McFarland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 (2000) 1012-1017
79. Aas J., Gessert C.E., and Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36 (2003) 580-585
80. Dendukuri N., Costa V., McGregor M., and Brophy J.M. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 173 (2005) 167-170
81. Hickson M., D'Souza A.L., Muthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. Br Med J 335 (2007) 80
82. Viscidi R., Laughon B.E., Yolken R., Bo-Linn P., Moench T., Ryder R.W., et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 148 (1983) 93-100
83. Aronsson B., Granström M., Möllby R., and Nord C.E. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13 (1985) 97-101
84. Kyne L., Warny M., Qamar A., and Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 (2000) 390-397
85. Kyne L., Warny M., Qamar A., and Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357 (2001) 189-193
86. Drudy D., Calabi E., Kyne L., Sougioultzis S., Kelly E., Fairweather N., et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 41 (2004) 237-242
87. Kelly C.P., Pothoulakis C., Orellana J., and LaMont J.T. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 102 (1992) 35-40
88. Johnson S., Gerding D.N., and Janoff E.N. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. J Infect Dis 166 (1992) 1287-1294
89. Jiang Z.D., Garey K.W., Price M., Graham G., Okhuysen P., Dao-Tran T., et al. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol 5 (2007) 964-968
90. Torres J.F., Lyerly D.M., Hill J.E., and Monath T.P. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 63 (1995) 4619-4627
91. Giannasca P.J., Zhang Z.X., Lei W.D., Boden J.A., Giel M.A., Monath T.P., et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 67 (1999) 527-538
92. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128 (2005) 764-770